Niosomes are vesicular, novel drug delivery system that helps to release the drugs in a sustained, regulated and targeted manner and also helps to enhance the oral bioavailability of water insoluble drug. Valsartan is selective angiotensin (II) type-1 receptor (AT1) antagonist and employed in the treatment of hypertension. Due to poor aqueous solubility and poor absorption from oral route, it is failed to provide effective plasma drug profile on conventional oral delivery. This investigation is focused on a niosomal formulation to enhance its bioavailability. Valsartan niosomal suspension was made using two methods: thin film hydration and ether injection, using non-ionic surfactants span 60 and tween 20. Compatibility, solubility, entrapment efficiency, vesicle size, surface shape, and stability tests were performed on the niosomal formulations. The results of the FT-IR investigation revealed that drug and other excipients had no interaction. Valsartan has been found to be more soluble in methanol. The formulated niosomes were spherical in shape. The entrapment effectiveness was determined to be somewhere between 72 and 82 percent. In comparison to other formulations, the formulation produced using the thin film hydration technique (F1B) had the highest % of Valsartan. F1B formulation was selected for further studies. Particle size of FIB formulation was founded 200 nm. Formulation appeared stable under refrigerated condition and showed greater stability, whereas storage at room temperature showed less stability.